AML-193細(xì)胞，人急性單核細(xì)胞白血病

簡要描述：AML-193細(xì)胞，人急性單核細(xì)胞白血病單核細(xì)胞
ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和*培養(yǎng)條件！

產(chǎn)品型號：CRL-9589
廠商性質(zhì)：生產(chǎn)廠家
更新時(shí)間：2025-08-14
訪問量：2332

產(chǎn)品咨詢聯(lián)系我們

產(chǎn)品分類

Product Category

細(xì)胞庫

細(xì)胞原代牛、狗、雞、鴨、魚原代細(xì)胞羊原代細(xì)胞豬原代細(xì)胞兔原代細(xì)胞小鼠原代細(xì)胞大鼠原代細(xì)胞人原代細(xì)胞培養(yǎng)基原代細(xì)胞凍存液 ATCC 人乳腺癌豬正常細(xì)胞豬睪丸細(xì)胞系人膠質(zhì)瘤細(xì)胞人成骨細(xì)胞人永生化肝細(xì)胞人肝癌細(xì)胞人卵巢癌細(xì)胞人結(jié)直腸腺癌人經(jīng)典小細(xì)胞肺癌細(xì)胞人小細(xì)胞肺癌細(xì)胞人結(jié)直腸腺癌細(xì)胞人鼻腔上皮細(xì)胞中國倉鼠卵巢懸浮細(xì)胞嗜性逆轉(zhuǎn)錄病毒包裝穩(wěn)定細(xì)胞株小鼠神經(jīng)細(xì)胞瘤人眼脈洛膜黑色素瘤 PT67 逆轉(zhuǎn)錄酶病毒包裝細(xì)胞鴨子胚胎成纖維細(xì)胞豬腎細(xì)胞系昆蟲細(xì)胞貓腎細(xì)胞恒河猴胚腎細(xì)胞倉鼠卵巢細(xì)胞負(fù)鼠腎細(xì)胞倉鼠肺細(xì)胞果蠅胚胎細(xì)胞家貓肺成纖維樣細(xì)胞雞胚細(xì)胞豚鼠心肌來源細(xì)胞豚鼠肺成纖維樣細(xì)胞豚鼠皮膚成纖維樣細(xì)胞狗腎細(xì)胞非洲綠猴胚胎腎上皮細(xì)胞猴胚胎腎上皮細(xì)胞長臂猿淋巴瘤新生牛眼囊成纖維細(xì)胞黑化大家鼠肺成纖維樣細(xì)胞俄勒岡地鼠細(xì)胞家兔皮膚成纖維樣細(xì)胞昆蟲卵巢細(xì)胞人胸膜瘤細(xì)胞非洲綠猴腎細(xì)胞 VERO 衍生株（SVP）白化金黃地鼠肺成纖維樣細(xì)胞黃胸鼠肺成纖維樣細(xì)胞白鰱尾鰭細(xì)胞蝙蝠肺細(xì)胞草魚腎細(xì)胞系大黃魚腎細(xì)胞猴腎細(xì)胞系犬腎細(xì)胞系人結(jié)腸直腸腺癌豬肺泡巨噬細(xì)胞 PFHSA05（TLL2）人重組特洛德樣蛋白因子 PFHSA04 （BMP1）人重組骨誘導(dǎo)因子人乳腺癌細(xì)胞結(jié)腸癌細(xì)胞成纖維細(xì)胞人胚腎細(xì)胞動(dòng)物卵巢細(xì)胞動(dòng)物胚胎細(xì)胞動(dòng)物肺細(xì)胞肋骨來源細(xì)胞成纖維樣細(xì)胞動(dòng)物上皮細(xì)胞動(dòng)物肝臟細(xì)胞可誘導(dǎo)表達(dá)穩(wěn)定細(xì)胞株動(dòng)物氣管細(xì)胞動(dòng)物腎細(xì)胞動(dòng)物巨噬細(xì)胞人正常細(xì)胞人腫瘤細(xì)胞、癌細(xì)胞小鼠正常細(xì)胞小鼠腫瘤細(xì)胞、癌細(xì)胞大鼠正常細(xì)胞大鼠腫瘤細(xì)胞其它動(dòng)物細(xì)胞查看全部產(chǎn)品

相關(guān)文章

詳細(xì)介紹

AML-193細(xì)胞，人急性單核細(xì)胞白血病單核細(xì)胞

ATCC^® Number:	CRL-9589™	Price:
Designations:AML-193Depositors:Wistar InstituteBiosafety Level:1 AML-193細(xì)胞，人急性單核細(xì)胞白血病單核細(xì)胞Shipped:frozenMedium & Serum:See PropagationGrowth Properties:suspensionOrganism:Homo sapiensMorphology:lymphoblast Source:Organ: peripheral blood Disease: acute monocytic leukemia Cell Type: monocyte;Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.Antigen Expression:CD15, human; Homo sapiens, expressed (75 to 95% of the cells) (75 to 95% of the cells)DNA Profile (STR):Amelogenin: X CSF1PO: 11,12 D13S317: 12 D16S539: 12 D5S818: 9,13 D7S820: 9,12 THO1: 7,9 TPOX: 8,9 vWA: 15,17Cytogenetic Analysis:This is a hyperdiploid human cell line. The modal chromosome number is 49, occurring in 50% of cells. The rate of polyploidy is 2.2%. There is one marker chromosome, der(17)t(17;17)(p13.1;q21.3), that occurred in every cell. These cells are trisomic for N3, N6, N8, and N13, and occasionally also for N2. N17 and X chromosome had a single copy, but occasionally the X had two copies. Thus the modal karyotype of this cell line is 49, X, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3), -17. The subline with 50, X, +2, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3), -17 and 50, XX, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3, -17 also occurred, but at a very low frequency.Age:13 yearsGender:female 單核細(xì)胞Comments:Interleukin-3 (interleukin 3, IL-3) and granulocyte/macrophage colony stimulating factor (GM-CSF) act synergistically to stimulate growth of the cells. Granulocyte colony stimulating factor (G-CSF) also supports short term and long term growth of AML-193 cells and acts synergistically with GM-CSF in inducing proliferation of the cells.This line was formerly designated ATCC HTB-188.Propagation:ATCC complete growth medium: Iscove's modified Dulbecco's medium with 0.005 mg/ml insulin, 0.005 mg/ml transferrin and 5 ng/ml GM-CSF, 95%; fetal bovine serum, 5%.Temperature: 37.0°C Growth Conditions: The cells are dependent upon GM-CSF for long term growth. Conditioned medium from U-87MG (ATCC HTB-14) may be used at a concentration of 10% to replace the GM-CSF in the medium (see J. Immunol. 139:3348- 3354, 1987).Subculturing:Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 X 10(5) cells/ml and maintain between 3 X 10(5) and 1 X 10(6) cells/ml. Medium Renewal: Every 2 to 3 daysPreservation:Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phaseRelated Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005recommended serum:ATCC 30-2020References:22617: Lange B, et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 70: 192-199, 1987. PubMed: 349613223467: Santoli D, et al. Synergistic and antagonistic effects of recombinant human interleukin (IL) 3, IL-1 alpha, granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines. J. Immunol. 139: 3348-3354, 1987. PubMed: 3500218

產(chǎn)品咨詢

留言框

產(chǎn)品：
您的單位：
您的姓名：
聯(lián)系電話：
常用郵箱：
省份：
詳細(xì)地址：
補(bǔ)充說明：
驗(yàn)證碼：

請輸入計(jì)算結(jié)果（填寫阿拉伯?dāng)?shù)字），如：三加四=7

上一篇：HTB-19BT-20細(xì)胞，人乳癌細(xì)胞
下一篇：CRL-2265CEM/C1細(xì)胞，人急性淋巴細(xì)胞白血病細(xì)胞

AML-193細(xì)胞， 人急性單核細(xì)胞白血病

留言框

產(chǎn)品：

您的單位：

您的姓名：

聯(lián)系電話：

常用郵箱：

省份：

詳細(xì)地址：

補(bǔ)充說明：

驗(yàn)證碼：

AML-193細(xì)胞，人急性單核細(xì)胞白血病